Clinical Trial Search

Primary: Number of Brain Scans in Healthy Young Adults Subjects Which do Not Show Amyloid — 181; 0; 123; 58 Brain Scans Read

Primary: Remission of Depressive Symptoms — 14; 14 participants

Primary: Myocardial Fatty Acid Uptake Rate — 18.492; 2.123; 36.005; 7.8 umol/min/100g

Primary: Completion of Two PET/CT Scans Per Patient as Dictated by Assigned Arm — 30; 30; 40 PET/CT scans

Primary: The Sensitivity of Blinded Visual Interpretations of [18F]Flutemetamol Positron Emission Tomography (PET) Images Without Anatomic Brain Images for Detecting Brain…

Primary: Absolute Accuracy of SUV Max of PET/CT vs PET/MRI — 1.78; 1.08; 0.54; 0.51 ratio

Primary: Sensitivity — NA Participants

Primary: Compare the Biodistribution of 11C-acetate Positron Emission Tomography (PET)/Computed Tomography (CT) Imaging in Tumor and Non Tumorous Regions of the Prostate — 4.4…

Primary: Frequency of Breast Imaging Assessment Reporting and Data System (BI-RADS) "0" Call-back in Mammography vs Breast Imaging Assessment Reporting and Data System (BI-RADS)…

Primary: Percentage of Participants Alive Without Local-regional Progression [Local-regional Progression-free (LRPF) Survival] at Two Years (NRG) — 59.5; 54.6 percentage of…

Primary: Change in Dopamine Levels at Baseline and After Drug of Dependence Administration as Confirmed by PET Images. — 0.0388; 0.033; 0.0285; 0.0368 mm^3

Primary: Emax D1 Dopamine — 81.9 percentage

Primary: Overall Image Quality Scores

Primary: Number Usable PET/MRI Image Sets — 70 Usable image sets

Primary: Number of Participants With Intraveneous Infiltration of FDG During Routine PET/CT Imaging by Visually Assessment of Interpreting Physicians — 17; 32 Participants

Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability After 89Zr-Trastuzumab Administration — 1; 1 participants

Primary: Change in PBR Uptake (Changes in PBR Uptake by PET) — 1.301; 1.1219 percent change from baseline

Primary: Overall Survival — 91.6 weeks

Primary: Progression-Free Survival (PFS) at 36-Months for Patients Who Received 4 Cycles of ABVD — .91 proportion of patients

Primary: Number of Detected Uptakes on PET Images — 47; 54; 74; 74 number of real metastatic lesions — p=<0.001

Primary: Summary of Sensitivity of the Blinded Visual PET Image Interpretations Without Anatomic Images. — 94; 92; 90; 94 Percentage (True Positive)

Primary: Complete Pathological Response (pCR) of PET/CT Non-responders — 17.95; 20 percentage of participants with a pCR — p=1.0

Primary: True Positive Rate for Detection of Tumor Location in Lymph Nodes Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up

Primary: Inter-observer (B1 and B2) Reproducibility of the PET-CT by Anatomical Regions — 0.7254; 0.7854; 0.7597; 0.6711 Weighted kappa concordance coefficient

Primary: Safety and Tolerability of Combined Exercise and Regadenoson Stress — 0; 3; 3; 0 Participants

Primary: Reproducibility Coefficient (RDC) Between the Two Imaging Modalities in Liver Tumor Tissues — 16.9 percent difference

Primary: Sensitivity of Imaging Modalities for the Detection of ACTH-secreting Non-pituitary Tumor in Patients — 96.3; 77.1; 66.7; 100 percentage of patients

Primary: Percentage of Participants With at Least (>=) 1 Responding Bone Lesion Assessed by Total Sodium Fluoride (NaF) Standardized Uptake Value [SUVtotal] at Third 18F-NaF…

Primary: Number and Percentage of Tumors With Complete, Circumferential Ablation Margin Visibility During FDG PET/CT-guided Liver Ablations (AP-PET-1 v. Contrast-enhanced MRI)…

Primary: Attenuation Correction for PET/MRI, Assessed Using Standard Uptake Values (SUVs) (Cohorts I & II)